Cancer Family
Malignant Digestive System Neoplasm
CI-CAN-00000229Explore in graph →
4,262 active trials43 approved drugs556 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000229Explore in graph →
Clinical trials
19,101 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2,000)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04249739 | Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive | unknown | Phase 2 | 93 | Samsung Medical CenterOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT03951337 | 64Cu-ATSM PET/CT in Rectum Cancer (TEP 64Cu-ATSM-Rectum) | unknown | Phase 2 | 70 | Institut Cancerologie de l'OuestOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05111860 | Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy | unknown | Phase 1 / Phase 2 | 20 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06280690 | SGM-101 Tumor Targeted Fluorescence Endoscopy in Rectal Polyps With Suspected T1 Adenocarcinoma or High Grade Dysplasia(SGM-T1) | unknown | Phase 2 | 20 | Leiden University Medical CenterOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06284746 | Tirelizumab Combined With Chemotherapy in the Treatment of HER-2 Negative Locally Advanced Gastric Cancer | unknown | Phase 2 | 80 | Lin ChenOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05122091 | Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma | unknown | Phase 2 | 53 | Guangxi Medical UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT04096417 | Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations | unknown | Phase 2 | 14 | Academic and Community Cancer Research UnitedOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03474822 | Plasmodium Immunotherapy for Breast and Liver Cancers | unknown | Phase 1 / Phase 2 | 60 | CAS Lamvac Biotech Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06266871 | SOX Combined With Tislelizumab and LDRT for Neoadjuvant Treatment of Locally Advanced Gastric Cancer | unknown | Phase 1 / Phase 2 | 64 | West China HospitalOTHER | 0 | Feb 20, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06262581 | Neoadjuvant Tisleizumab(BGB-A317) for dMMR/MSI-H Non-late Stage CRC Patients Before Surgery | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT06255262 | Durvalumab Combined With Surufatinib as Maintenance Therapy in Patients With Advanced Biliary Tract Cancer | unknown | Phase 1 / Phase 2 | 30 | China Medical University, ChinaOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT05029102 | TAS-102 and Anlotinib in ≥3 Lines mGC | unknown | Phase 2 | 45 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT04844385 | Toripalimab Plus Neoadjuvant Chemotherapy Combined With Chemoradiotherapy for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 124 | Sun Yat-sen UniversityOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT06074029 | Exploratory Study on the Therapeutic Effect Prediction Model of Advanced BTC Immunotherapy | unknown | Phase 1 / Phase 2 | 50 | Peking Union Medical College HospitalOTHER | 1 | Feb 8, 2024 | clinicaltrials |
| NCT05980689 | Combination of AK104 and Neoadjuvant Chemoradiotherapy in pMMR/MSS Locally Advanced Rectal Cancer | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT05933980 | Toripalimab,Celecoxib and Regorafenib in the Treatment of Refractory Advanced Colorectal Cancer(REGOTORICOX) | unknown | Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT01515787 | PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery | unknown | Phase 2 / Phase 3 | 1,194 | Alliance for Clinical Trials in OncologyOTHER | 4 | Feb 2, 2024 | clinicaltrials |
| NCT05743504 | Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients | unknown | Phase 1 / Phase 2 | 32 | National Taiwan University HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05291156 | CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy | unknown | Phase 2 | 173 | University of Campania Luigi VanvitelliOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT03503630 | Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma | unknown | Phase 2 | 44 | Ali ShamseddineOTHER | 2 | Jan 31, 2024 | clinicaltrials |
| NCT06231017 | Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer | unknown | Phase 2 | 36 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT06227325 | Disitamab Vedotin Combined With Sintilimab and XELOX Perioperative Treatment for Resectable Gastric Caner With HER2 Overexpression | unknown | Phase 2 | 27 | Henan Cancer HospitalOTHER_GOV | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT06202014 | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC | unknown | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 19, 2024 | clinicaltrials |
| NCT05435313 | Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy | unknown | Phase 2 | 39 | Fudan UniversityOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05962450 | Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy | unknown | Phase 2 | 84 | Beijing YouAn HospitalOTHER | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04617457 | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas(HOLIPANC) | unknown | Phase 2 | 150 | University of CologneOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT05955157 | Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma | unknown | Phase 2 / Phase 3 | 52 | University of MalayaOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06198465 | Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma | unknown | Phase 2 | 24 | Xijing HospitalOTHER | 1 | Jan 10, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06197438 | Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | unknown | Phase 2 | 36 | Fujian Cancer HospitalOTHER_GOV | 0 | Jan 9, 2024 | clinicaltrials |
| NCT02037048 | FOLFOX-6 Induction Chemotherapy Followed by Esophagectomy and Post-operative Chemoradiotherapy in Patients With Esophageal Adenocarcinoma | unknown | Phase 2 | 63 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05522738 | Safety and Efficacy of Fruquintinib+FOLFIRI in RAS-mutated Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 46 | Chinese PLA General HospitalOTHER | 1 | Jan 8, 2024 | clinicaltrials |
| NCT05626569 | Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05859477 | Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric Cancer(NIVOFGFR2) | unknown | Phase 2 | 23 | Kidney Cancer Research BureauOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06171854 | caBozantinib in Pre-treated pAtients With Metastatic COlorectal Cancer.(ABACO) | unknown | Phase 2 | 33 | University of Campania Luigi VanvitelliOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT06186609 | PD-1 Inhibitor Combined With Radiotherapy for Elderly ESCC | unknown | Phase 2 | 68 | Affiliated Hospital of Nantong UniversityOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04329429 | A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer | unknown | Phase 2 | 57 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 20, 2023 | clinicaltrials |
| NCT05839197 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC(CCGLC-010) | unknown | Phase 2 | 38 | Wan-Guang ZhangOTHER | 1 | Dec 19, 2023 | clinicaltrials |
| NCT06172634 | A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy(DICI_PC) | unknown | Phase 1 / Phase 2 | 10 | Soonchunhyang University HospitalOTHER | 0 | Dec 15, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Mar 13, 2024source: clinicaltrials